Biocept Inc (NASDAQ:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced that President and Chief Executive Officer Michael Nall will participate in a panel discussion at the Cantor Fitzgerald Inaugural Healthcare Conference being held Wednesday, July 8, 2015, at the Le Parker Meridien Hotel in New York City. The panel, “Liquid Biopsies: The benefits and challenges ahead for CTCs, ctNDA, and exosomes,” will be held at 2:30 p.m. Eastern time.

“We appreciate Cantor Fitzgerald’s focus on the promising field of liquid biopsy and are delighted to participate on this panel,” said Mr. Nall. “We see a clear benefit of using a simple blood draw to help physicians personalize their patients’ treatment by monitoring disease status to adjust treatment when necessary. At Biocept, our proprietary platform has the ability to capture and analyze both circulating tumor cells (CTCs) and cell free circulating tumor-associated DNA (ctDNA), and we have commercialized novel test panels for breast, gastric and lung cancers.”(Original Source)

Shares of Biocept Inc. closed last Thursday at $2.64. BIOC has a 1-year high of $6.68 and a 1-year low of $1.09. The stock’s 50-day moving average is $2.96 and its 200-day moving average is $2.66.

Biocept Inc is acancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample or liquid biopsy.